文献速递神经介入CTDSA

光子计数探测器CT用于血流导向装置治疗颅内动脉瘤非同期随访的图像质量与可行性评估

Assessment of image quality and feasibility of Photon-Counting detector CT for the Non-Contemporaneous follow-up of intracranial aneurysms treated with flow diverter stents.
PubMed 文献 · Eur J Radiol · 2026-08-31

本回顾性队列研究纳入30例(32个动脉瘤)血流导向装置治疗后以PCD-CT随访的患者,比较PCD-CT与术中基线DSA及VasoCT的图像质量。PCD-CT支架管腔可见度显著高于DSA和VasoCT,诊断信心高于VasoCT但略低于DSA,有效剂量为亚毫西弗级。PCD-CT是有前景的无创随访工具,但需前瞻性验证其诊断支架内狭窄的准确性。

要点

  • PCD-CT支架管腔可见度评分显著优于基线DSA和VasoCT。
  • PCD-CT诊断信心高于VasoCT,但略低于DSA。
  • PCD-CT有效剂量0.79 mSv,全脑覆盖导致剂量高于局部DSA和VasoCT。

核心结论

  • PCD-CT较基线DSA和VasoCT提供更优的支架管腔可视化,同时维持亚毫西弗辐射剂量,是有前景的无创随访工具。

研究设计与样本

  • 回顾性队列研究,纳入30例患者(32个动脉瘤),血流导向装置治疗后中位6.5个月行PCD-CT随访,以术中基线DSA和VasoCT为对照。
  • 三名神经介入医师在不知临床数据的情况下,采用5点Likert量表评估支架管腔可见度和诊断信心。
  • 定量指标包括信噪比、对比噪声比、相对金属伪影宽度和辐射剂量,并采用混合线性模型分析图像质量的预测因素。

关键影像表现/征象

  • PCD-CT支架管腔可见度评分(4.6 ± 0.7)显著高于基线DSA(3.0 ± 0.5,P < 0.001)和VasoCT(3.1 ± 1.2,P < 0.001)。
  • PCD-CT诊断信心评分(4.8 ± 0.6)显著高于VasoCT(3.4 ± 1.0,P < 0.001),但略低于DSA(5.0 ± 0.0,P = 0.031)。
  • 观察者间一致性极好(ICC ≥ 0.945)。
  • 混合模型显示PCD-CT是管腔可见度的最强正向预测因素(β = 1.65,P < 0.001),该优势在不同动脉瘤形态和主要支架设计中保持稳健。

诊断标准与关键数值

  • 支架管腔可见度和诊断信心均采用5点Likert量表评分,由三名神经介入医师独立评估。
  • PCD-CT有效剂量为0.79 ± 0.07 mSv,高于局部DSA的0.13 ± 0.02 mSv和VasoCT的0.55 ± 0.08 mSv,原因为全脑覆盖。

临床应用与阅片要点

  • PCD-CT可作为血流导向装置治疗后非同期随访的无创影像手段,支架管腔显示优于VasoCT,可减少对DSA的依赖。
  • 需注意PCD-CT全脑覆盖导致辐射剂量高于局部DSA和VasoCT,应在保证图像质量前提下优化扫描方案。
  • PCD-CT诊断信心略低于DSA,对疑似支架内狭窄的判读仍需结合临床及必要时的DSA确认。

局限性

  • 回顾性研究设计,样本量较小(30例患者、32个动脉瘤),单中心经验。
  • 随访为非同期比较,PCD-CT与术中基线DSA和VasoCT的扫描时间点不同。
  • 尚未前瞻性验证PCD-CT诊断支架内狭窄的准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Noninvasive imaging is essential for long-term surveillance of flow diverter-treated intracranial aneurysms. We evaluate the image quality and feasibility of photon-counting detector CT (PCD-CT) in a real-world, non-contemporaneous follow-up setting, comparing it with intraoperative baseline DSA and flat-panel detector CT (VasoCT).

METHODS: This retrospective cohort study included 30 patients (32 aneurysms) followed with PCD-CT (median: 6.5 months) after flow diverter treatment. Three neurointerventionalists, blinded to clinical data, assessed stent lumen visibility and diagnostic confidence using a 5-point Likert scale. Quantitative metrics included signal-to-noise ratio, contrast-to-noise ratio, relative metal artifact width, and radiation doses. A mixed linear model identified predictors of image quality.

RESULTS: PCD-CT stent lumen visibility (4.6 ± 0.7) was significantly higher than baseline DSA (3.0 ± 0.5, P < 0.001) and VasoCT (3.1 ± 1.2, P < 0.001). Diagnostic confidence scores were significantly higher for DSA (5.0 ± 0.0) and PCD-CT (4.8 ± 0.6) than for VasoCT (3.4 ± 1.0, both P < 0.001), while PCD-CT was slightly but significantly lower than DSA (P = 0.031). Inter-observer agreement was excellent (ICC ≥ 0.945). PCD-CT effective dose (0.79 ± 0.07 mSv) was higher than localized DSA (0.13 ± 0.02 mSv) and VasoCT (0.55 ± 0.08 mSv) due to whole-brain coverage. Mixed model identified PCD-CT as the strongest positive predictor for lumen visibility (β = 1.65, P < 0.001), and this advantage remained robust across different aneurysm morphologies and the predominant stent designs evaluated in this cohort.

CONCLUSION: PCD-CT provides superior stent lumen visualization compared to baseline imaging, while maintaining a sub-millisievert radiation dose. It represents a promising non-invasive surveillance tool, though prospective validation of its diagnostic accuracy for in-stent stenosis is required.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Gao JP, Bian Y, Zhang RJ, et al. Assessment of image quality and feasibility of Photon-Counting detector CT for the Non-Contemporaneous follow-up of intracranial aneurysms treated with flow diverter stents. Eur J Radiol. 2026. PMID: 42691745. doi:10.1016/j.ejrad.2026.113203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。